|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China显示文摘Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. | MA Yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU Jin Ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 | 2020 | Biomedical and Environmental Sciences2020，33，12： | 8 |
| 2 | Blocking of N-acetylglucosaminyltransferase V induces cellular endoplasmic reticulum stress in human hepatocarcinoma 7721 cells显示文摘N-acetylglucosaminyltransferase V (GnT-V ) 是重要 tumorigenesis 和联系转移的酶。为了学习它的简历,工作, GnT-V 稳定地压制了房间线(GnT-V-AS/7,721 ) 在以前的学习从 7,721 个 hepatocarcinoma 房间被构造。在这研究, cDNA 数组基因表示侧面在 GnT-V-AS/7,721 之间被比较并且父母 7,721 个房间。数据显示 GnT-V-AS/7,721 显示出与 ER 压力一致的一个典型表达式模式。ER 压力的分子的机制被分析在二展开的蛋白质回答(UPR ) 在关键分子上在 GnT-V-AS/7,721 探索小径。为 ATF6 和 Ire1/XBP-1 小径,它被 BIP 的起来规定在 mRNA 和蛋白质证实 XBP-1 的拼接的形式的水平,和外观。至于 PERK/eIF2alpha 小径,激活嗯 eIF2alpha kinase 津贴被观察。从 GnT-V-AS/7,721 房间证实结果,在 UPR 的关键分子在 7,721 个房间再被检验由特定的 RNAi 处理防碍 GnT-V。结果与从 GnT-V-AS/7721 的那些是类似的,显示那块 GnT-V 能明确地激活嗯在 7,721 个房间的应力。率(3 )H 人加入与率改正了(3 ) 在 GnT-V-AS/7,721 的 H 列伊加入与控制相比极大地是下面调整的,它表明了综合的酶的缺乏的功能在堵住的 GnT-V 以后的 N-glycans。而且,与 underglycosylation 联系的女伴 GRP94 的更快的移居形式,和细胞内部的 glycoproteins 的广泛地改变的 N-glycans 结构是也在 GnT-V-AS/7,721 检测了。这些结果支持了机制损害的那块 GnT-V 表达式女伴和 N-glycan-synthesizing 酶工作,它在 vivo 引起了 UPR。 | Huan Fang Wei Huang Ying Ying Xu Zong Hou Shen Chao Qun Wu Shou Yi Qiao Yan Xu Long Yu Hui Li Chen | 2006 | Cell Research2006，16，1： | 7 |
| 3 | Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization显示文摘 | Si-Long Qin Xian-Jun Chen Xin Xu Jian-Zhong Shou Xin-Gang Bi Liang Ji Ya-Ling Han Yan Cai Fang Wei Jian-Hui Ma Min Wu Qi-Min Zhan Ming-Rong Wang | 2005 | Cancer Letters2005，，2： | 1 |
| 4 | Molecularly imprinted solid phase extraction coupled to highperformance liquid chromatography for determination of trace dichlorvos residues in vegetables 显示文摘 | XU Zhixiang FANG Guozhen WANG Shou | 2010 | Food Chem2010，119，2： | 1 |
| 5 | Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma显示文摘Objective To determine the mRNA and protein levels of urokinase plasminogen activator receptors(u PAR) in bone marrow fluid and bone marrow tissue from multiple myeloma(MM) patients and assess association of u PAR level with prognosis of MM.Methods u PAR levels in bone marrow fluid of 22 MM patients at the stable and progressive stages and 18 iron deficiency anemia patients with normal bone marrow(control) were examined by ELISA.Furthermore,u PAR expression in bone marrow tissue was investigated by RT-PCR and Western blot,respectively.The distribution of u PAR in MM cells was examined using immunofluorescence staining.The pathological changes in different stages of MM patients were studied by HE staining.Results u PAR level in bone marrow fluid of MM patients(1.52±0.32 μg/ml) was found to be higher than that in the control group(0.98±0.15 μg/ml).Interestingly,u PAR protein(0.686±0.075 vs.0.372±0.043,P<0.05) and m RNA(2.51±0.46 vs.4.46±1.15,P<0.05) expression levels of MM patients at the progressive stage were significantly higher than those at the stable stage.The expression of u PAR in MM bone marrow was confirmed by immunofluorescence staining.Moreover,HE staining revealed a great increased number of nucleated cells and severe impairment of hematopoietic function in the bone marrow of patients with progressive-stage myeloma.Conclusion Our study reveals that u PAR expression is positively correlated with the development and progress of MM. | Li-hong Shou Dan Cao Xiao-hui Dong Qiu Fang Bao-lian Xu Ju-ping Fei | 2016 | Chinese Medical Sciences Journal2016，31，3： | 0 |
| 6 | Recent advances in traction drive technology for rail transit显示文摘The traction drive system is the“heart”of rail transit vehicles.The development of sustainable,secure,economic,reliable,efficient,and comfortable contemporary rail transportation has led to increasingly stringent requirements for traction drive systems.The interest in such systems is constantly growing,supported by advancements such as permanent magnet(PM)motors,advanced electronic devices such as those using silicon carbide(SiC),new-generation insulating materials such as organic silicon,and advanced magnetic materials such as rare-earth magnets and amorphous materials.Progress has also been made in control methods,manufacturing technology,artificial intelligence(AI),and other advanced technologies.In this paper,we briefly review the state-of-the-art critical global trends in rail transit traction drive technology in recent years.Potential areas for research and the main obstacles hindering the development of the next-generation rail transit traction drive systems are also discussed.Finally,we describe some advanced traction drive technologies used in actual engineering applications. | Jien MA Chao LUO Lin QIU Xing LIU Bowen XU Jiabo SHOU Youtong FANG | 2023 | Journal of Zhejiang University-Science A(Applied Physics & Engineering)2023，24，3： | 0 |
| 7 | 3-to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge:Results from a Prospective,Multicenter Study显示文摘Objective Coronavirus disease 2019(COVID-19)and tuberculosis(TB)are major public health and social issues worldwide.The long-term follow-up of COVID-19 with pulmonary TB(PTB)survivors after discharge is unclear.This study aimed to comprehensively describe clinical outcomes,including sequela and recurrence at 3,12,and 24 months after discharge,among COVID-19 with PTB survivors.Methods From January 22,2020 to May 6,2022,with a follow-up by August 26,2022,a prospective,multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13 hospitals from four provinces in China.Clinical outcomes,including sequela,recurrence of COVID-19,and PTB survivors,were collected via telephone and face-to-face interviews at 3,12,and 24 months after discharge.Results Thirty-two COVID-19 with PTB survivors were included.The median age was 52(45,59)years,and 23(71.9%)were men.Among them,nearly two-thirds(62.5%)of the survivors were moderate,three(9.4%)were severe,and more than half(59.4%)had at least one comorbidity(PTB excluded).The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6%at 3 months to 15.8%at 24 months,with anxiety having a higher proportion over a follow-up.Cough and amnesia recovered at the 12-month follow-up,while anxiety,fatigue,and trouble sleeping remained after 24months.Additionally,one(3.1%)case presented two recurrences of PTB and no re-positive COVID-19during the follow-up period.Conclusion The proportion of long symptoms in COVID-19 with PTB survivors decreased over time,while nearly one in six still experience persistent symptoms with a higher proportion of anxiety.The recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention. | WANG Jing Ya ZONG Xing Yu WU Gui Hui QI Yuan Lin LI Hui Zhen JI Xin Yu TONG Lin ZHANG Lei YANG Ming Bo YANG Pu Ye LI Ji Ke XIAO Fu Rong ZHANG Lin Song HU Yun Hong LIU Hong De XU Shou Fang SUN Sheng WU Wei MAO Ya LI Min Qing HOU Hao Hua GONG Zhao Yuan GUO Yang JIAO Li Wen QIN Jin WANG Ding Yi WANG Fang GUAN Li LIN Gang MA Yan WANG Yan Ping SHI Nan Nan | 2022 | Biomedical and Environmental Sciences2022，35，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员